Ozempic and Mounjaro: Impacts on Health and Weight Loss
Recent studies have revealed both positive and negative implications of popular weight-loss and diabetes medications, Ozempic and Mounjaro. These drugs, primarily used to treat type 2 diabetes, have shown effectiveness in improving blood sugar control and promoting weight loss. However, emerging evidence raises concerns regarding muscle mass loss and potential risks for pregnant women.
Muscle Loss Concerns
A significant article published in The Lancet highlights the critical issue of muscle loss associated with the use of GLP-1 agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide). Research conducted by experts from the Pennington Biomedical Research Center indicates that muscle loss can account for 25% to 39% of total weight lost over 36 to 72 weeks. This rate is considerably higher than typical muscle loss seen with non-pharmacological calorie restriction or normal aging.
The authors of the study emphasize the importance of maintaining skeletal muscle mass, as it plays vital roles in metabolic health, physical strength, and immune function. Decreased muscle mass can lead to increased health risks, such as poor glucose regulation and a higher likelihood of infections. To mitigate these risks, the researchers advocate for a multimodal approach to weight management, which combines GLP-1 agonists with exercise and nutritional interventions to preserve muscle mass.
Risks for Pregnant Women
In addition to concerns about muscle loss, experts warn against the use of these weight-loss injections by postpartum women. Reports have surfaced of new mothers using Ozempic and Mounjaro to lose weight rapidly after childbirth, potentially exposing themselves and their infants to unknown risks. Professor Alex Miras from the University of Ulster cautions that these medications should not be used for cosmetic purposes or by breastfeeding mothers, as the drugs may pass through breast milk.
Charlotte Griffiths, a new mother who experienced severe side effects after accidentally overdosing on Wegovy (another GLP-1 medication), highlights the dangers of using these drugs irresponsibly. Health professionals stress that these medications should only be prescribed to individuals with a BMI of at least 30 and related health conditions, such as diabetes.
Positive Outcomes for Kidney Health
On a more positive note, a recent international study led by clinical pharmacologist Hedo L. Herspinck has found that Ozempic may also benefit patients with chronic kidney disease. The study, published in Nature Medicine, showed that semaglutide injections significantly reduced protein levels in urine, indicating decreased kidney damage, alongside improvements in blood pressure and weight loss.
Participants reported feeling less hungry, leading to reduced food intake, which further contributed to their weight loss and improved health outcomes. Herspinck expressed optimism about the drug's dual benefits on kidney health, stating, 'The great thing is that the drug has both direct and indirect effects on the kidneys.'
Conclusion
While Ozempic and Mounjaro offer promising benefits for diabetes management and weight loss, the growing evidence of potential muscle loss and risks for postpartum women necessitates caution. Future research should focus on developing strategies to mitigate these risks while maximizing the benefits of these medications.
